Compare Sterling Biotech with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ALEMBIC PHARMA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH ALEMBIC PHARMA STERLING BIOTECH/
ALEMBIC PHARMA
 
P/E (TTM) x -0.4 15.6 - View Chart
P/BV x 0.0 3.6 0.4% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 STERLING BIOTECH   ALEMBIC PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ALEMBIC PHARMA
Mar-19
STERLING BIOTECH/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs11664 1.6%   
Low Rs3412 0.8%   
Sales per share (Unadj.) Rs26.8208.7 12.8%  
Earnings per share (Unadj.) Rs-15.031.0 -48.3%  
Cash flow per share (Unadj.) Rs-5.537.1 -14.7%  
Dividends per share (Unadj.) Rs05.50 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs54.9144.2 38.1%  
Shares outstanding (eoy) m267.87188.52 142.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.6 10.1%   
Avg P/E ratio x-0.517.4 -2.7%  
P/CF ratio (eoy) x-1.314.5 -8.8%  
Price / Book Value ratio x0.13.7 3.4%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m1,862101,461 1.8%   
No. of employees `0001.4NA-   
Total wages/salary Rs m5477,467 7.3%   
Avg. sales/employee Rs Th5,303.3NM-  
Avg. wages/employee Rs Th403.8NM-  
Avg. net profit/employee Rs Th-2,959.0NM-  
INCOME DATA
Net Sales Rs m7,18139,347 18.2%  
Other income Rs m4394 45.4%   
Total revenues Rs m7,22339,441 18.3%   
Gross profit Rs m9478,736 10.8%  
Depreciation Rs m2,5431,152 220.7%   
Interest Rs m4,377184 2,377.6%   
Profit before tax Rs m-5,9317,493 -79.1%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,568 -122.8%   
Profit after tax Rs m-4,0075,844 -68.6%  
Gross profit margin %13.222.2 59.4%  
Effective tax rate %32.420.9 155.1%   
Net profit margin %-55.814.9 -375.7%  
BALANCE SHEET DATA
Current assets Rs m14,33519,577 73.2%   
Current liabilities Rs m49,80914,896 334.4%   
Net working cap to sales %-494.011.9 -4,152.5%  
Current ratio x0.31.3 21.9%  
Inventory Days Days40390 449.5%  
Debtors Days Days17145 376.3%  
Net fixed assets Rs m55,43227,097 204.6%   
Share capital Rs m268377 71.1%   
"Free" reserves Rs m13,93526,811 52.0%   
Net worth Rs m14,70127,188 54.1%   
Long term debt Rs m9,4784,993 189.8%   
Total assets Rs m73,98847,778 154.9%  
Interest coverage x-0.441.7 -0.9%   
Debt to equity ratio x0.60.2 351.1%  
Sales to assets ratio x0.10.8 11.8%   
Return on assets %0.512.6 4.0%  
Return on equity %-27.321.5 -126.8%  
Return on capital %-6.423.6 -27.2%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86019,453 9.6%   
Fx outflow Rs m256,065 0.4%   
Net fx Rs m1,83513,388 13.7%   
CASH FLOW
From Operations Rs m1,7198,120 21.2%  
From Investments Rs m-3,148-7,556 41.7%  
From Financial Activity Rs m1,426590 241.5%  
Net Cashflow Rs m-31,153 -0.3%  

Share Holding

Indian Promoters % 33.9 74.1 45.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.9 -  
FIIs % 9.9 9.1 108.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 13.9 282.7%  
Shareholders   21,482 49,328 43.5%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS